

## Results Update

Monday, 16 November 2009



**TA SECURITIES HOLDINGS BERHAD**  
 Menara TA One, 22 Jalan P Ramlee,  
 50250 Kuala Lumpur, Malaysia  
 Tel : 603 - 2072 1277  
 Fax : 603 - 2032 5048

KLCI : 1,270.96  
 Bloomberg : PHRM MK

Analyst : TA Research

Tel : 20721277 ext : 1616

e-mail : ikmalhafizi@ta.com.my

Get your facts  
 before you invest

**CBRS**  
 FREE Expert  
 Analysis Reports

## Pharmaniaga Berhad

Surprisingly Disappointing

Share Price : RM4.40

Target Price : RM4.70

Market Capitalisation : RM107mn

Board : Main

Sector : Pharmaceutical

Recommendation : SELL

Stock code : 8133

## Key Stock Statistics

		2007	2008	2009F	2010F
EPS	(sen)	46.8	39.8	47.8	78.6
P/E	(x)	7.5	8.8	7.4	4.5
Div / Share	(sen)	18.0	11.9	14.3	23.6
BV / Share	(sen)	3.4	3.7	4.1	4.7
Issued Capital	(mn)	107			
52 weeks price	(%)	4.04 / 3.10			
Major shareholders		Khazanah - 86%			


## Per Share Data

		2007	2008	2009F	2010F
Book Value	(sen)	3.4	3.7	4.1	4.7
Cash Flow	(sen)	- 1.2	95.9	118.9	165.7
Earnings	(sen)	46.8	39.8	47.8	78.6
Gross Dividend	(sen)	18.0	11.9	14.3	23.6
Dividend Yield	(%)	5.1	3.4	4.1	6.7
PER	(x)	7.5	8.8	7.4	4.5
ROE	(%)	15.6	11.1	12.2	17.6

## P&amp;L Analysis (RM mil)

	2007	2008	2009F	2010F
Revenue	1184.0	1338.9	1482.8	1646.6
Cost of Revenue	1080.8	1237.4	1386.1	1506.5
EBITDA	103.2	101.5	96.7	140.1
Net Interest	5.4	9.5	7.2	5.4
Depreciation	21.6	21.9	22.3	22.7
Net Profit	50.1	42.6	51.1	84.1

## Share Price chart



Source : Bloomberg

## 3Q09 Results Analysis

				Cumulative 3Q		
YE 31 December	3Q09	2Q09	QOQ%	FY09	FY08	YOY%
Turnover	329.9	333.2	-1%	976.89	977.40	0%
EBIT	10.4	25.4	-59%	57.2	70.8	-19%
Interest Inc/(exp)	-1.0	-1.1	-7%	-3.30	-4.70	-30%
Pretax	9.4	24.3	-61%	53.95	66.10	-18%
Taxation	-3.0	-5.8	-48%	-14.34	-22.62	-37%
Net Profit	6.1	17.7	-66%	38.28	42.24	-9%
EPS (sen)	5.7	16.5	-66%	35.78	39.49	-9%
EBIT Margin (%)	3%	8%		6%	7%	
Pretax Margin (%)	3%	7%		6%	7%	
Tax Rate (%)	32%	24%		27%	34%	

## Review

- Pharmaniaga's 3Q09 results were announced last Friday. The group made RM6,059mn in net profit or 5.66sen per share. The performance is backed by revenue of around RM330mn.
- The results came well below our estimate as cumulatively, it made up only 59% of our full year estimate of RM64.9mn in net income.
- Compared to the preceding quarter, the group's revenue was rather flat. However, as a result of tremendous contraction in gross profit margin and lower contribution from other income, net profit declined by 66%. The lower margin is a result of higher costs of raw materials.
- YTD 9M09 net profit fell by some 9% YoY.

### Impact

- Given the sudden increase in cost inputs, we are adjusting our FY09 numbers. This would reduce our gross profit margin to 14.7% from 15.8%.
- This would reduce our FY09 net profit to RM51.1mn (-26.34%) from RM64.9mn estimated previously.
- We are also reducing our FY10 forecast, in tandem with the 2.3p.p reduction in gross profit margin. This translates to FY10 net profit of RM84.1mn vs. RM107.8mn previously.

### Outlook

- The company has asked for an extension of its listing status. This is because it is in breach of the required public shareholding spread. We believe this issue is a big concern plaguing sentiments of its share trading activities.

### Valuation

- We are rolling forward our valuation basis to FY10. Assuming an unchanged PER of 6x, we derive at a TP of RM4.70, from RM3.95. With this we maintain our SELL stance on Pharmaniaga.

### Disclaimer

The information in this report has been obtained from sources believed to be reliable. Its accuracy or completeness is not guaranteed and opinions are subject to change without notice. This report is for information only and not to be construed as a solicitation for contracts. We accept no liability for any direct or indirect loss arising from the use of this document. We, our associates, directors, employees may have an interest in the securities and/or companies mentioned herein.

*This report has been prepared by TA SECURITIES HOLDINGS BERHAD for purposes of CMDF-Bursa Research Scheme ("CBRS") administered by Bursa Malaysia Berhad and has been compensated to undertake the scheme. TA SECURITIES HOLDINGS BERHAD has produced this report independent of any influence from CBRS or the subject company.*

*For more information about CBRS and other research reports, please visit Bursa Malaysia's website at:  
[http://www.bursamalaysia.com/website/bml/listed\\_companies/cmdf\\_bursa\\_research\\_scheme/](http://www.bursamalaysia.com/website/bml/listed_companies/cmdf_bursa_research_scheme/)*

for TA SECURITIES HOLDINGS BERHAD<sup>(14948-M)</sup>  
(A Participating Organisation of Bursa Malaysia Securities Berhad)  
Yaw Chun Soon, Executive Director – Operations